Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Shareholder Meeting (August 2025)
14 slides from Amplia Therapeutics's shareholder meeting presentation, Aug 27, 2025
Slide 1: CEO & Managing Director's Presentation to Annual General Meeting
ASX RELEASE 27 August 2025 CEO & Managing Director’s Presentation to Annual General Meeting Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to release the CEO & Managing Director’s presentation to the Company’s Annual General Meeting (YE 31 March 2
Slide 2: Annual General Meeting
For personal use only Annual General Meeting 27 August 2025 Chris Burns PhD GAICD FAHMS ampliatx.com | @ampliatx 1
Slide 3: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operat
Slide 4: Executive Summary
EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development For personal use only Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer US trial of narmafotinib in pa
Slide 5: Company Summary
COMPANY SUMMARY ASX: ATX ATX Price and Volume - 12 months Share price For personal use only $0.188 (26 Aug 2025) Share price range $0.049 - 0.42 (52 week low/high) Shares on issue 486.48M Market capitalization $91.2M (approx.) (26 Aug 2025) 4
Slide 6: Metastatic Pancreatic Cancer
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Median Progression Median Overall Treatment Tolerability For personal use only Free Survival Survival Gemcitabine + Abraxane ® 5.5 months 8.5 months 3% (MPACT study) FOLFIRINOX 6.4 mon
Slide 7: The Amplia Advantage
THE AMPLIA ADVANTAGE Three critical features For personal use only Efficacy Narmafotinib Tolerability Durability 6
Slide 8: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Median Progression Free Survival (mPFS) data All ACCENT patients @ 400 mg (n = 64) For personal use only Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months) Interim data w
Slide 9: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability ACCENT Trial MPACT Trial Excellent response rate observed (Narmafotinib/Gemcitabine/ (Gemcitabine/ 1 confirmed Complete Response Abraxane) Abraxane) For personal use only 16 confirmed Partial Responses CR 2% 0.2% I
Slide 10: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden For personal use only Adverse Events (Grade 3 or above) Narmafotinib +Gem/Abr Gem/Abr Gem/Abr FOLFIRINOX NAL
Slide 11: AMPLICITY Trial
AMPLICITY TRIAL Phase 1b/2a study in Pancreatic Cancer in the US and Australia Objective To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed For personal use only metastatic patients To identify recommended phase 2 dose (RP2D) Entry from clinicaltrials.gov/st
Slide 12: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) For personal use only CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. Preclinical data ACCENT study KRAS INHIBITORS RADIOTHERAPY Preclinical data, incl. Published data coll
Slide 13: Upcoming Milestones
UPCOMING MILESTONES For personal use only Q3 2025 Q4 2025 Q1 2026 Q2 2026 2H 2026 ACCENT top-line data ACCENT further patient ACCENT mature data ACCENT trial completion ACCENT full data release updates (including OS) possible ACCENT request FDA type AMPLICITY 2-dose comparison trial C meeting - Phas
Slide 14: Thank You
For personal use only THANK YOU Chris Burns PhD GAICD FAHMS CEO and MD chris@ampliatx.com Amplia Therapeutics Limited ASX: ATX info@ampliatx.com ampliatx.com 13
Amplia Therapeutics — Shareholder Meeting (August 2025) on 6ix